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TO THE EDITOR
Anti-tumor necrosis factor-a (TNF-a)
drugs (mAbs infliximab (IFX) and
adalimumab (ADA), and soluble TNF-
a receptor etanercept (ETA)) are used
for rheumatoid arthritis (RA), spondy-
larthropathies, psoriasis, Crohn’s dis-
ease, and ulcerative colitis. These
molecules increase the risk of various
pathogens such as Mycobacterium tu-
berculosis (Flynn et al., 1995; Tubach
et al., 2009) or trigger reactivation of
varicella zoster virus (VZV) and
subsequently herpes zoster (HZ). The
Spanish registry showed more frequent
hospitalizations because of VZV
infection for patients receiving anti-
TNF-a therapy than expected in the
general population (Garcı´a-Doval
et al., 2010), and the German registry
demonstrated an increased risk of
HZ and severe HZ as well (Strangfeld
et al., 2009). We aimed to identify
the risk factors and describe the out-
come of HZ for patients receiving TNF-
a blockers for severe inflammatory
conditions.
The French RATIO registry was
designed to prospectively collect all
cases of opportunistic infections in
metropolitan France from 1 February
2004 to 31 January 2007 in patients
who were receiving or had received
anti-TNF-a treatment. This registry in-
cludes cases from clinicians, pharma-
covigilance centers of the French
agency of drugs (Agence Franc¸aise de
Se´curite´ Sanitaire des Produits de
Sante´), and companies commercializ-
ing anti-TNF-a therapy. The methodo-
logical details have been described
elsewhere (Tubach et al., 2005, 2009).
A committee of three experts in oppor-
tunistic infections (OC, DS-C, and OL)
reviewed detailed standardized case
report forms and additional documents
for all reported HZ cases. We con-
ducted a case–control study to investi-
gate the risk factors of HZ for patients
receiving anti-TNF-a therapy. Cases
were validated HZ cases being treated
for a labeled indication, and controls
were patients from centers involved in
the RATIO registry who were being
treated with anti-TNF-a therapy (current
treatment or stopped for o24 months)
for a labeled indication and never
exhibited HZ during the follow-up
period. The control pool has been
described elsewhere (Salmon-Ceron
et al., 2011). Four controls per case
were matched by underlying inflamma-
tory disease.
We validated 24 HZ cases (18
women, mean age 54.4 years, 79%
receiving anti-TNF-a therapy for RA,
median time from onset of last anti-TNF
agent to HZ occurrence 11.5 years
(interquartile range 4.2–24.3)). Clinical
characteristics and outcomes are shown
in Table 1. The last anti-TNF agent
received was ADA, IFX, and ETA in
10 (14.7%), 9 (37.5%), and 5 (20.8%)
cases, respectively. Eight cases, invol-
ving at least two distinct episodes, more
than one dermatome, the central ner-
vous system, or the eye, were consid-
ered severe HZ, as recently defined
by the RATIO group (Salmon-Ceron
et al., 2011): one clinically sympto-
matic meningitis with positive local
results on PCR, four multidermatomal
locations, one secondary generalized
and recurrent HZ, and three ophthalmic
Abbreviations: ADA, adalimumab; ETA, etanercept; HZ, herpes zoster; IFX, infliximab; RA, rheumatoid
arthritis; TNF-a, tumor necrosis factor-a; VZV, varicella zoster virus
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HZ (including two keratitis). After HZ
diagnosis, anti-TNF-a therapy was
stopped for 16 patients (66.7%), but
was still ongoing for 7 patients (2 ETA
and 5 IFX). After a median follow-up of
35.3 (29.9–36.5) months, one patient
died from an HZ-unrelated cause,
one experienced two relapses, despite
receiving valaciclovir as chemoprophy-
laxis, and one presented postherpetic
pain; the other cases were cured.
Multivariate analysis (Table 2) of
data for the 24 HZ cases and 96
controls showed a decreased risk of
HZ with increasing time since the last
anti-TNF-a agent, with no significant
difference by anti-TNF-a agent. When
considering anti-TNF-a agents in two
classes, the risk of HZ was significantly
greater with monoclonal anti-TNF-a
antibodies than with soluble receptor.
Sensitivity analysis varying the defini-
tion of exposure (by anti-TNF-a agent,
for patients currently receiving anti-
TNF-a therapy, those who received
anti-TNF-a therapy for at least 6 weeks,
and those who received only one anti-
TNF-a agent) showed a higher risk
with ADA and IFX than ETA, statisti-
cally significant in only some sub-
groups. In the subgroup of severe HZ,
the risk was higher, but not significant,
with mAbs than with soluble receptor
(P¼0.06).
Our results suggest an increased risk
of HZ with monoclonal anti-TNF-a
antibodies than with soluble TNF-a
receptor. This result agrees with those
from the German register RABBIT
(Strangfeld et al., 2009). The difference
in the risk of HZ between the two classes
of anti-TNF-a therapy may be explained
by their different mechanisms of action
(Wallis, 2008). Moreover, a similar
result was observed in the risk of
tuberculosis reactivation (Dixon et al.,
2007; Tubach et al., 2009), legio-
nellosis, and other severe opportunistic
infections (Salmon-Ceron et al., 2011).
In addition, we found that the risk
of HZ was higher at the beginning of
anti-TNF-a therapy. This result agrees
with those from a Swedish study sug-
gesting increased risk of hospitalization
with infection in general in the first year
of anti-TNF-a therapy, but decreased
thereafter (Askling et al., 2007). HZ,
which results from the reactivation of
VZV, occurs early during immunosup-
pression, after bone marrow transplan-
tation (Steer et al., 2000), solid organ
transplantation (Gourishankar et al.,
2004), or during HIV infection, when
CD4 cell count might still be rela-
tively preserved (Moore and Chaisson,
1996).
One-third of our HZ patients receiv-
ing anti-TNF-a agents showed severe
HZ. For these cases, subgroup analysis
also showed a higher risk, but not
significant, with mAbs than with solu-
ble receptor. Some HZ cases reported
in trials are severe and may present
as encephalitis with neurological seq-
uelae (Keystone et al., 2004), with
one report of death due to bacterial
superinfection complicated by necro-
tizing fasciitis (Furst et al., 2003).
The German register RABBIT reported
15 cases of multidermatomal or HZ
ophthalmicus, with an incidence of
2.5/1,000 patient-years for patients
receiving anti-TNF-a agents: 3.7 for
mAbs, 0.8 for ETA, and 0.9 for controls
(Strangfeld et al., 2009).
The main limitation of this study
analysis is that our data for HZ episodes
may not be exhaustive because of
underreporting; therefore, we did not
aim to determine HZ incidence in
patients receiving anti-TNF-a agents,
and the sample size was very limited.
More severe infections were more
likely to be reported (relative over-
representation of severe cases because
of lack of exhaustivity of nonsevere
cases), but probably did not differ by
anti-TNF-a agent.
The next step should be better
management of prevention and treat-
ment of HZ in patients receiving anti-
TNF-a agents, including the value of
vaccination before treatment.
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